1. Home
  2. NCRA vs AKTX Comparison

NCRA vs AKTX Comparison

Compare NCRA & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$0.82

Market Cap

13.2M

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.29

Market Cap

14.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
AKTX
Founded
2002
N/A
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
14.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCRA
AKTX
Price
$0.82
$0.29
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$3.30
AVG Volume (30 Days)
79.4K
1.9M
Earning Date
04-01-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,106,275.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.72
$0.22
52 Week High
$2.40
$1.73

Technical Indicators

Market Signals
Indicator
NCRA
AKTX
Relative Strength Index (RSI) 45.58 40.46
Support Level $0.78 $0.25
Resistance Level $0.95 $0.31
Average True Range (ATR) 0.14 0.04
MACD 0.01 0.01
Stochastic Oscillator 31.15 32.71

Price Performance

Historical Comparison
NCRA
AKTX

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: